MEI Pharma, Inc.
MEIP
MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor that is in Phase III clinical trial for the treatment of patients with relapsed/refractory follicular lymphoma, as well as in Phase Ib multi-arm trial to treatā¦ read more
Healthcare
Biotechnology
19 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$4.89
Price-0.21%
-$0.01
1Y
Price
Market Cap
$32.581m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financials Overview
Key metrics over the past few years-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow MarginRevenue
$0.00
-
1y CAGR-
3y CAGR-
5y CAGREarnings
-$31.663m
-
1y CAGR-
3y CAGR-
5y CAGREPS
-$4.75
-
1y CAGR-
3y CAGR-
5y CAGRBook Value
$19.541m
$20.779m
Assets$1.238m
Liabilities-
DebtDebt to Assets
0.00%
-
Debt to EBITDAFree Cash Flow
-$36.382m
-
1y CAGR-
3y CAGR-
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company